A counterfeit version of onabotulinumtoxinA (Botox) was found in the United States and may have been sold to doctors’ offices and medical clinics nationwide. The version is considered unsafe and should not be used.
The U.S. Pharmacopeial Convention recently joined a number of other global health organizations in the Fight the Fakes campaign to combat the growing problem of counterfeit and substandard medications.
Eight experts discussed their views on the counterfeit market at the recent Vegas Cosmetic Surgery and Aesthetic Dermatology meeting in Las Vegas. Susan Weinkle, M.D., Bradenton, Fla., who moderated the panel, summed up the group’s consensus by stating, “Patient safety needs to be first and foremost. We need to use products that have been evaluated, that companies have put their research dollars behind to have data to support using them safely in our patients.”